The United States is grappling with the most severe COVID-19 surge since 2022, characterised by a sharp increase in hospitalisation rates and intensified viral activity. Recent data from the Centers for Disease Control and Prevention (CDC) highlights a troubling rise in hospitalisation rates, which have surged from one person per 100,000 in May to four […]
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative Phase 2b KEYNOTE-942/mRNA-4157-P201 study. This clinical trial evaluates mRNA-4157 (V940), an innovative individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, for patients with resected high-risk melanoma (stage […]
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation by the US Food and Drug Administration (FDA). The breakthrough therapy designation for the combination is for its use as adjuvant treatment of high-risk melanoma in patients […]
Moderna has agreed to acquire OriCiro Genomics, a Japanese biotech firm involved in developing cell-free synthesis and amplification of plasmid DNAs for applications in gene or cell-based therapies and synthetic biology. The consideration to be paid by the American biotech company for the acquisition is $85 million. Moderna believes that the synthetic biology and enzyme […]
Moderna has entered into a 15-year collaboration agreement with Thermo Fisher Scientific to enable dedicated large-scale US manufacturing of Spikevax, the former’s Covid-19 vaccine as well as other investigational messenger RNA (mRNA) medicines in its pipeline. The agreement is said to make use of exclusive commercial fill-finish manufacturing capacity in the US for mRNA vaccines […]
Moderna has signed an agreement in principle with the Government of Australia to build a messenger RNA (mRNA) vaccine manufacturing plant in Victoria. According to the US biotech company, the planned framework will lay the foundation to help Australia get direct access to rapid response capabilities to pandemics as well as to gain access to […]
Moderna will invest up to $500 million to construct a messenger RNA facility (mRNA facility) in Africa with an aim to produce up to 500 million doses of vaccines annually at the 50 µg dose level. The US biotech company said that the new facility will have capabilities for drug substance manufacturing with the scope […]
US biotech company Moderna has been given emergency use authorization from the Indian government for its Covid-19 Vaccine Moderna (mRNA-1273) in adults aged 18 years and older. In this connection, the company has been given a registration certificate from the government along with permission to import the vaccine to India for restricted use in an […]
Moderna has signed a manufacturing services and supply agreement with Samsung Biologics under which the latter will undertake large scale, commercial fill-finish manufacturing for the mRNA-1273 COVID-19 vaccine. According to Samsung Biologics, technology transfer will begin immediately at the company’s facilities in Incheon, South Korea. The South Korean CDMO will use a production line equipped […]
Moderna has agreed to supply the Philippines with seven million additional doses of Covid-19 Vaccine Moderna, to take the confirmed order commitment to the Asian country to up to 20 million doses. The US biotech company said that the seven million additional doses have been secured under a partnership with the private sector. Currently, the […]